Press Releases Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 09/05/2026 am IST			5-day change	1st Jan Change
19.96 ^USD	-4.06%		-7.14%	-7.27%

08/05	Sarepta Therapeutics' Commercial Portfolio Alone Should Support Higher Valuation, Wedbush Says	MT
07/05	Sarepta Therapeutics, Inc., Q1 2026 Earnings Call, May 06, 2026

Press Releases

07/05	Sarepta Therapeutics : 1Q 2026 Earnings Results Presentation	PU
07/05	Sarepta Therapeutics: Q1 Earnings Snapshot	AQ
07/05	Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments	BU
22/04	Sarepta Therapeutics to Announce First Quarter 2026 Financial Results	BU
01/04	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
25/03	Sarepta Therapeutics : Preliminary Phase 1 2 Clinical Data Readout for DM1 and FSHD Programs	PU
25/03	Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1	BU
25/03	Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1	BU
20/03	Sarepta Provides Regulatory Update on AMONDYS 45(R) and VYONDYS 53(R)	AQ
19/03	Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®	BU
16/03	Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne	BU
12/03	Sarepta Therapeutics : MDA 2026 EMBARK 3yr vs EC Presentation FINAL	PU
09/03	Sarepta Therapeutics : MDA 2026 Pooled Overall Safety Poster & Supplement FINAL	PU
09/03	Sarepta Therapeutics : MDA 2026 EMBARK 3 year vs EC Poster & Supplement FINAL	PU
09/03	Sarepta Therapeutics : MDA 2026 ESSENCE Topline Results Poster and Supplement FINAL	PU
09/03	Sarepta Therapeutics : MDA 2026 ENDEAVOR C1 C3 Encore Poster FINAL	PU
09/03	Sarepta Therapeutics : MDA 2026 EMBARK Part 2 Treated CaGI Poster & Supplement FINAL	PU
09/03	Sarepta Therapeutics : MDA 2026 EVOLVE IA4 Poster FINAL	PU
09/03	Sarepta Therapeutics : MDA 2026 PMO Mortality Poster & Supplement FINAL	PU
09/03	Sarepta Therapeutics : MDA 2026 Dystrophin Quantification Poster FINAL	PU
09/03	Sarepta Therapeutics : MDA 2026 9004 102 Expression & Safety Poster FINAL	PU
27/02	Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program	BU
26/02	Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress	BU
26/02	Sarepta Therapeutics: Q4 Earnings Snapshot	AQ
26/02	Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments	BU